In contrast, treatment with an isotype-control antibody, or depletion of CD4+ T cells, TCRγδ+ T cells, NK cells, or Gr-1+ myeloid cells, did not prevent SCC tumour rejection (Figure 1D). This evidence concerns the gene CD4 and neoplasm.